NCT05191680View on ClinicalTrials.gov

TherApeutics in Early ProState Cancer (TAPS02)

PHASE2RecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

April 24, 2023

Primary Completion Date

October 31, 2029

Study Completion Date

October 31, 2029

Conditions
Prostate Cancer
Interventions
DRUG

Apalutamide Oral Tablet [Erleada]

Apalutamide is a selective Androgen Receptor (AR) inhibitor that binds directly to the ligand-binding domain of the AR.

DRUG

Placebo

Placebo to match apalutamide

Trial Locations (6)

CB2 0QQ

RECRUITING

Addenbrooke's Hospital, Cambridge

BS10 5NB

RECRUITING

Southmead Hospital, Bristol

IP33 2QZ

RECRUITING

West Suffolk Hospital, Bury St Edmunds

DA2 8DA

RECRUITING

Darent Valley Hospital, Dartford

E1 1FR

RECRUITING

St Bartholomew's Hospital, London

SW3 6JJ

RECRUITING

The Royal Marsden Hospital - Chelsea, London

All Listed Sponsors
collaborator

University of Cambridge

OTHER

collaborator

Janssen-Cilag Ltd.

INDUSTRY

lead

Cambridge University Hospitals NHS Foundation Trust

OTHER